biote Business Summary

Biote Corp. (BTMD) operates a vertically integrated practice-building platform specializing in bioidentical hormone replacement therapy (BHRT) and therapeutic wellness. The company generates revenue through two primary segments: service fees from its proprietary "Biote Method"—which provides healthcare practitioners with clinical education, certification, and practice management software—and the sale of Biote-branded dietary supplements. A key competitive advantage is its ownership of Asteria Health, a 503B outsourcing facility that enables internal manufacturing of hormone pellets, driving significant gross margin expansion through supply chain control. Biote competes with pharmaceutical and wellness firms such as Enanta Pharmaceuticals, Aclaris Therapeutics, and Elysium Health, positioning itself as a premium, end-to-end solutions provider for independent clinics seeking to implement personalized preventive medicine. Founded in 2012 by Dr. Gary Donovitz, a pioneer in subcutaneous hormone pellet therapy, Biote is currently led by CEO Bret Christensen, who took the helm in February 2025 following a distinguished career in the medical device and women’s health sectors. The executive leadership team includes Bob Peterson as CFO and Chief Business Officer, John Olsen as Chief Information Officer, and Kevin Key as Chief Digital Officer, collectively bringing decades of experience in high-growth IT and healthcare operations. The company’s strategic direction is overseen by a board chaired by Marc Beer, former CEO of LFB Biotechnologies, and includes notable directors such as Rich Barrera. Biote maintains a robust institutional investor base, with significant positions held by 325 Capital, Bandera Partners, BlackRock, and Vanguard.